Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into past cases to find best brain tumor treatments for stomach cancer patients

NCT ID NCT07448493

Knowledge-focused Sponsor: Blokhin's Russian Cancer Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make better treatment decisions in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

230 people

The number who actually took part.

Started

Feb 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥ 18 years) with histologically confirmed adenocarcinoma of the stomach, adenocarcinoma or squamous cell carcinoma of the esophagus, or adenocarcinoma of the gastroesophageal junction, and radiologically ± histologically documented brain metastases. Patients referred after initial local treatment for brain metastases are included provided that complete documentation of the first treatment modality is available.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients aged 18 years or older; * Histologically confirmed epithelial malignancy of the stomach (gastric adenocarcinoma), esophagus (esophageal adenocarcinoma), or gastroesophageal junction (GEJ adenocarcinoma). Patients with squamous cell carcinoma of the esophagus are also eligible; * Radiologically ± histologically confirmed brain metastases, including: * Solid brain parenchymal metastases * Leptomeningeal disease (LMD) * Both solid metastases and LMD Exclusion Criteria: * Synchronous or metachronous multiple primary malignancies (MPM) involving sites other than the stomach, esophagus, or gastroesophageal junction; * Primary tumor located outside the stomach, esophagus, or gastroesophageal junction; * Histologically confirmed non-epithelial gastrointestinal malignancy (e.g., neuroendocrine tumors, sarcoma, gastrointestinal stromal tumor, lymphoma); * Isolated spinal cord involvement without brain parenchymal metastases; * Incomplete medical records precluding assessment of at least one primary endpoint (OS, TTIP, or CNS-PFS). Patients with available data for any primary endpoint are eligible, even if other clinical details are missing. * Prior local treatment for brain metastases at an outside institution with no available records, precluding determination of the first local treatment modality

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases Esophageal cancer Gastric cancer

Contacts and locations

Locations

  • A.S. Loginov Moscow Clinical Scientific Center

    Moscow, 111123, Russia

  • Blokhin's Russian Cancer Research Center

    Moscow, 115478, Russia

  • Federal Center of Neurosurgery

    Tyumen, 625062, Russia

  • Gamma Knife Center Moscow

    Moscow, 125047, Russia

  • Gomel Regional Clinical Oncology Dispensary (OKOD)

    Homyel, 246012, Belarus

  • Kaliningrad Regional Clinical Oncology Center

    Kaliningrad, 236016, Russia

  • Moscow Multidisciplinary Clinical Center "Kommunarka"

    Moscow, 117303, Russia

  • Moscow Regional Oncology Hospital No. 62

    Krasnogorsk, 143442, Russia

  • N.N. Burdenko National Medical Research Center of Neurosurgery

    Moscow, 125047, Russia

  • N.N. Petrov National Medical Research Center of Oncology

    Saint Petersburg, 197758, Russia

  • N.V. Sklifosovsky Research Institute for Emergency Medicine

    Moscow, 129090, Russia

  • OncoStop CyberKnife Center

    Moscow, 115478, Russia

  • P.A. Hertsen Moscow Oncology Research Institute

    Moscow, 125284, Russia

  • Republican Clinical Oncology Dispensary (RCOD)

    Ufa, 450054, Russia

  • S.S. Yudin City Clinical Hospital, Oncology Center No. 1

    Moscow, 115446, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.